CBD-Rich Cannabis

How it works

Cannabinoids work through the endocannabinoid system — CB1 and CB2 receptors densely expressed in the gut’s nervous system and immune cells. CB1 activity helps calm gut motility and reduces pain signalling; CB2 activity supports balanced immune function. CBD works through additional routes, including FAAH inhibition (which raises the body’s own cannabinoid, anandamide) and TRPV1 signalling. Together, these support comfort, appetite, sleep and overall wellbeing.

Traditional use

Cannabis has a long history in traditional medicine for digestive complaints, pain and appetite. It entered Western medicine in the 1830s and was widely used for gastrointestinal conditions in the 19th century.

Highlights

• In a 56-person randomised trial, Crohn’s activity scores fell from 282 to 166 on CBD-rich cannabis oil, versus 264 to 237 on placebo.
• Quality-of-life scores improved consistently across studies.
• Supports appetite, sleep and comfort — areas that matter deeply to daily life with Crohn’s.
• Endoscopic scores did not change in the trial, so it is best used for comfort and symptom support alongside care that addresses inflammation.
• Hemp-derived CBD (under 0.3% THC) is widely available; THC-containing products depend on local law.

What the research shows

Every study below links to its original publication so you can read it yourself. Many natural compounds have only been studied in small trials. That isn’t a verdict on them; it reflects how little funding exists for compounds that can’t be patented.

Using it alongside conventional care

Many people living with Crohn’s find cannabinoids help with the parts of life that medication doesn’t always reach — pain, appetite, sleep and overall quality of life. Because the trials showed symptom improvement without changes on endoscopy, the approach most people take is to use CBD for comfort alongside the therapies they and their gastroenterologist use to manage inflammation, such as Humira, Stelara, Skyrizi or Entyvio. That keeps the full picture visible to your care team. CBD can influence how some medications are metabolised, so share what you take with your doctor or pharmacist.

Never stop or change a prescribed medication without your gastroenterologist. Many people use natural support alongside conventional care, and your care team can help you do that safely.

Amounts used in research

Naftali 2021 used oil containing 160 mg/mL CBD and 40 mg/mL THC, titrated over 8 weeks. The 2013 trial used two cigarettes/day containing 115 mg THC. Both were add-ons to existing therapy.

Good to know

• THC-containing products cause sedation, cognitive impairment and dependence risk; CBD-dominant products less so.
• CBD inhibits CYP3A4 and CYP2C19 and can raise levels of co-administered drugs, including some immunosuppressants.
• Associated with elevated liver enzymes at higher CBD doses, especially alongside other hepatically cleared drugs.
• Cannabinoid hyperemesis syndrome can mimic a Crohn’s flare and is routinely missed.
• Legality varies by jurisdiction; unregulated products vary widely in actual cannabinoid content.

Community experiences

Sources

1. 1

   Oral CBD-rich cannabis induces clinical but not endoscopic response in patients with Crohn’s disease, a randomised controlled trial

   Naftali T, Bar-Lev Schleider L, Almog S, Meiri D, Konikoff FM. · Journal of Crohn’s and Colitis · 2021 · PMID 33858011

2. 2

   Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study

   Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM. · Clinical Gastroenterology and Hepatology · 2013 · PMID 23648372